
Lennie P G Derde

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4108629/publications.pdf Version: 2024-02-01



ENNIE P.C. DEDDE

#	Article	IF	CITATIONS
1	Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Medicine, 2020, 46, 854-887.	3.9	1,536
2	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 384, 1491-1502.	13.9	1,419
3	A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases, The, 2020, 20, e192-e197.	4.6	1,165
4	Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Critical Care Medicine, 2020, 48, e440-e469.	0.4	816
5	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	13.9	778
6	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 777-789.	13.9	712
7	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1317.	3.8	671
8	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	3.8	498
9	Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infectious Diseases, The, 2014, 14, 31-39.	4.6	297
10	Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Critical Care Medicine, 2021, 49, e219-e234.	0.4	289
11	The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired) Tj ETQq1 1 (0.784314 1.5	rgBT <u>/</u> Overloc 245
12	Personal protective equipment and intensive care unit healthcare worker safety in the COVID-19 era (PPE-SAFE): An international survey. Journal of Critical Care, 2020, 59, 70-75.	1.0	234
13	Adaptive platform trials: definition, design, conduct and reporting considerations. Nature Reviews Drug Discovery, 2019, 18, 797-807.	21.5	218
14	A guide to immunotherapy for COVID-19. Nature Medicine, 2022, 28, 39-50.	15.2	206
15	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nature Communications, 2021, 12, 2349.	5.8	194
16	Influenza-associated Aspergillosis in Critically III Patients. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 524-527.	2.5	176
17	Effect of Convalescent Plasma on Organ Support–Free Days in Critically III Patients With COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 1690.	3.8	169
18	MLST reveals potentially high-risk international clones of Enterobacter cloacae*. Journal of Antimicrobial Chemotherapy, 2015, 70, 48-56.	1.3	131

Lennie P G Derde

#	Article	IF	CITATIONS
19	Clinical impact and risk factors for colonization with extended-spectrum β-lactamase-producing bacteria in the intensive care unit. Intensive Care Medicine, 2012, 38, 1769-1778.	3.9	120
20	Chlorhexidine body washing to control antimicrobial-resistant bacteria in intensive care units: a systematic review. Intensive Care Medicine, 2012, 38, 931-939.	3.9	106
21	Anticoagulant interventions in hospitalized patients with COVIDâ€19: A scoping review of randomized controlled trials and call for international collaboration. Journal of Thrombosis and Haemostasis, 2020, 18, 2958-2967.	1.9	98
22	Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1247.	3.8	83
23	The Association Between Colonization With Carbapenemase-Producing Enterobacteriaceae and Overall ICU Mortality. Critical Care Medicine, 2015, 43, 1170-1177.	0.4	77
24	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Medicine, 2021, 47, 867-886.	3.9	65
25	The Transmissibility of Antibiotic-Resistant Enterobacteriaceae in Intensive Care Units. Clinical Infectious Diseases, 2018, 66, 489-493.	2.9	61
26	Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19. Journal of Infectious Diseases, 2021, 223, 1322-1333.	1.9	61
27	Duration of colonization with antimicrobial-resistant bacteria after ICU discharge. Intensive Care Medicine, 2014, 40, 564-571.	3.9	55
28	Randomised clinical trials in critical care: past, present and future. Intensive Care Medicine, 2022, 48, 164-178.	3.9	46
29	Molecular epidemiology of MRSA in 13 ICUs from eight European countries. Journal of Antimicrobial Chemotherapy, 2016, 71, 45-52.	1.3	43
30	Survey of metallo-β-lactamase-producing Enterobacteriaceae colonizing patients in European ICUs and rehabilitation units, 2008–11. Journal of Antimicrobial Chemotherapy, 2015, 70, 1981-1988.	1.3	41
31	Global outbreak research: harmony not hegemony. Lancet Infectious Diseases, The, 2020, 20, 770-772.	4.6	40
32	KPC-Like Carbapenemase-Producing Enterobacteriaceae Colonizing Patients in Europe and Israel. Antimicrobial Agents and Chemotherapy, 2016, 60, 1912-1917.	1.4	37
33	Characterization of pKP-M1144, a Novel ColE1-Like Plasmid Encoding IMP-8, GES-5, and BEL-1 β-Lactamases, from a Klebsiella pneumoniae Sequence Type 252 Isolate. Antimicrobial Agents and Chemotherapy, 2015, 59, 5065-5068.	1.4	30
34	Characterisation of IncA/C2 plasmids carrying an In416-like integron with the blaVIM-19 gene from Klebsiella pneumoniae ST383 of Greek origin. International Journal of Antimicrobial Agents, 2016, 47, 158-162.	1.1	25
35	Phylogenetic lineages, clones and β-lactamases in an international collection ofKlebsiella oxytocaisolates non-susceptible to expanded-spectrum cephalosporins. Journal of Antimicrobial Chemotherapy, 2015, 70, dkv273.	1.3	24
36	Antimicrobial stewardship in ICUs during the COVID-19 pandemic: back to the 90s?. Intensive Care Medicine, 2021, 47, 104-106.	3.9	22

Lennie P G Derde

#	Article	IF	CITATIONS
37	The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations. Lancet Infectious Diseases, The, 2022, 22, e153-e158.	4.6	22
38	Sudden cardiac arrest as a presentation of Brugada syndrome unmasked by thyroid storm. BMJ Case Reports, 2015, 2015, bcr2015212351.	0.2	16
39	Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis. PLoS ONE, 2022, 17, e0270668.	1.1	16
40	Oropharyngeal decontamination in intensive care patients: less is not more. Critical Care, 2009, 13, 183.	2.5	15
41	Statement paper on diversity for the European Society of Intensive Care Medicine (ESICM). Intensive Care Medicine, 2019, 45, 1002-1005.	3.9	14
42	Culture-based detection of methicillin-resistant Staphylococcus aureus by a network of European laboratories: an external quality assessment study. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 1765-1770.	1.3	11
43	The Diagnostic Yield of Routine Admission Blood Cultures in Critically III Patients. Critical Care Medicine, 2021, 49, 60-69.	0.4	9
44	Moderate positive predictive value of a multiplex real-time PCR on whole blood for pathogen detection in critically ill patients with sepsis. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1829-1836.	1.3	6
45	Thrombosis pathways in COVIDâ€19 versus influenzaâ€associated ARDS: a targeted proteomics approach. Journal of Thrombosis and Haemostasis, 2022, , .	1.9	4
46	Focus on clinical trial interpretation. Intensive Care Medicine, 2020, 46, 790-792.	3.9	2
47	Control of colonisation with extended-spectrum β-lactamase-producing bacteria: reply to Zandstra et al Intensive Care Medicine, 2013, 39, 540-540.	3.9	1
48	Contact Precautions for Patients With Multidrug-Resistant Pathogens. JAMA - Journal of the American Medical Association, 2015, 313, 629.	3.8	1
49	How COVID-19 will change the management of other respiratory viral infections. Intensive Care Medicine, 2021, 47, 1148-1151.	3.9	1
50	Care bundles in intensive care units – Authors' reply. Lancet Infectious Diseases, The, 2014, 14, 372.	4.6	0
51	The authors reply. Critical Care Medicine, 2015, 43, e537-e538.	0.4	Ο